Stainless steel ions stimulate increased thrombospondin-1-dependent tgf-beta activation by vascular smooth muscle cells: Implications for in-stent restenosis

Journal of Vascular Research

Volumn 47, Issue 4, 2010, Pages 309-322

  Pallero, Manuel A ^a   Talbert Roden, Melissa ^a   Chen, Yiu Fai ^b   Anderson, Peter G ^a   Lemons, Jack ^a   Brott, Brigitta C ^b   Murphy Ullrich, Joanne E ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Hydrogen peroxide; Restenosis; Smooth muscle cells; Stent corrosion; TGF ; Thrombospondin 1

Indexed keywords

CYCLIC GMP DEPENDENT PROTEIN KINASE; DESMIN; HYDROGEN PEROXIDE; METAL ION; STAINLESS STEEL; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; DOWN REGULATION; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IN-STENT RESTENOSIS; PHENOTYPE; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; AORTA; CATALASE; CELL SHAPE; CELLS, CULTURED; CORONARY RESTENOSIS; CORONARY VESSELS; CYCLIC GMP-DEPENDENT PROTEIN KINASES; DESMIN; EXTRACELLULAR MATRIX; FEMALE; HUMANS; HYDROGEN PEROXIDE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; OXIDATIVE STRESS; PHENOTYPE; PROSTHESIS DESIGN; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; STAINLESS STEEL; STENTS; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA;

EID: 72049096929     PISSN: 10181172     EISSN: None     Source Type: Journal    
DOI: 10.1159/000265565     Document Type: Article

References (72)

1. Scott NA: Restenosis following implantation of bare metal coronary stents: Pathophysiol-ogy and pathways involved in the vascular response to injury. Adv Drug Deliv Rev 2006; 58:358-376.
2. Santin M, Colombo P, Bruschi G: Interfacial biology of in-stent restenosis. Expert Rev Med Devices 2005; 2: 429-443.
3. Celik T, Iyisoy A, Jata B, Yuksel CU, Isik E: Stent fracture: a new villain of the village. Int J Cardiol 2008, E-pub ahead of print.
4. Kim JS, Lee SY, Lee JM, Yoon YW, Ahn CM, Kim MH, Min PK, Ko YG, Hong BK, Choi D, Kwon HM, Jang Y, Shim WH: Significant association of coronary stent fracture with in-stent restenosis in sirolimus-eluting stents. Coron Artery Dis 2009; 20:59-63.
5. Rits J, van Herwaarden JA, Jahrome AK, Krievins D, Moll FL: The incidence of arterial stent fractures with exclusion of coronary, aortic, and non-arterial settings. Eur J Vasc Endovasc Surg 2008; 36: 339-345.
6. Lee SH, Kim JG, Choi HW, Lee KR: Micro-tensile strain on the corrosion performance of diamond-like carbon coating. J Biomed Mater Res A 2008; 85:808-814.
7. Roy RK, Lee KR: Biomedical applications of diamond-like carbon coatings: a review. J Biomed Mater Res B Appl Biomater 2007; 83: 72-84.
8. Uo M, Watari F, Yokoyama A, Matsuno H, Kaw asa k i T: Tissue reac t ion a rou nd me t a l i m-plants observed by X-ray scanning analytical microscopy. Biomaterials 2001; 22:677-685.
9. Shih CC, Lin SJ, Chung KH, Chen YL, Su YY: Increased corrosion resistance of stent materials by converting current surface film of polycrystalline oxide into amorphous oxide. J Biomed Mater Res 2000; 52:323-332.
10. Shih CC, Shih CM, Chou KY, Lin SJ, Su YY: Stability of passivated 316l stainless steel oxide films for cardiovascular stents. J Biomed Mater Res A 2007; 80:861-873.
11. Koster R, Vieluf D, Kiehn M, Sommerauer M, Kahler J, Baldus S, Meinertz T, Hamm CW: Nickel and molybdenum contact allergies in patients with coronary in-stent reste-nosis. Lancet 2000; 356:1895-1897.
12. Santin M, Mikhalovska L, Lloyd AW, Mi-khalovsky S, Sigfrid L, Denyer SP, Field S, Teer D: In vitro host response assessment of biomaterials for cardiovascular stent manufacture. J Mater Sci Mater Med 2004; 15: 473-477.
13. Tucci M BR, Benqhuzzi H, Hughes J: Levels of hydrogen peroxide in tissues adjacent to failing implantable devices may play an active role in cytokine production. Biomed Sci Instrum 2000; 36:215-220.
14. Zhang P, Hatter A, Liu B: Manganese chloride stimulates rat microglia to release hydrogen peroxide. Toxicol Lett 2007; 173: 88-100.
15. Patel RP, Moellering D, Murphy-Ullrich J, Jo H, Beckman JS, Darley-Usmar VM: Cell signaling by reactive nitrogen and oxygen species in atherosclerosis. Free Radic Biol Med 2000; 28:1780-1794.
16. Chamberlain J: Transforming growth factor-ß: a promising target for anti-stenosis therapy. Cardiovasc Drug Rev 2001; 19:329-344.
17. Nabel EG, Shum L, Pompili VJ, Yang ZY, San H, Shu HB, Liptay S, Gold L, Gordon D, Derynck R, et al: Direct transfer of transforming growth factor ß 1 gene into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad Sci USA 1993; 90: 10759-10763.
18. Bornstein P, Agah A, Kyriakides TR: The role of thrombospondins 1 and 2 in the regulation of cell-matrix interactions, collagen fibril formation, and the response to injury. Int J Biochem Cell Biol 2004; 36: 1115-1125.
19. Murphy-Ullrich JE, Poczatek M: Activation of latent TGF-ß by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev 2000; 11:59-69.
20. Ribeiro SM, Poczatek M, Schultz-Cherry S, Villain M, Murphy-Ullrich JE: The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-ß. J Biol Chem 1999; 274: 13586-13593.
21. Murphy-Ullrich JE: Thrombospondin-de-pendent activation of latent TGF-ß in fibro-sis and disease; in Jakowlew SB (ed): Transforming growth factor-ß in cancer therapy. Totowa, Humana Press, 2008, vol I, pp 549-567.
22. Belmadani S, Bernal J, Wei CC, Pallero MA, Dell'italia L, Murphy-Ullrich JE, Berecek KH: A thrombospondin-1 antagonist of transforming growth factor-ß activation blocks cardiomyopathy in rats with diabetes and elevated angiotensin II. Am J Pathol 2007; 171: 777-789.
23. Hoffmann J, Simon P, Zimmermann AK, Le-mancyk M, Walter T, Beyer M, Hoffmeister HM, Ziemer G, Wendel HP: Thrombospon-din 1 as possible key factor in the hemocom-patibility of endocoronary prostheses. Biomaterials 2005; 26:5240-5250.
24. Chamberlain J, Gunn J, Francis SE, Holt CM, Arnold ND, Cumberland DC, Ferguson MW, Crossman DC: TGFß is active, and correlates with activators of tgfbeta, following porcine coronary angioplasty. Cardiovasc Res 2001; 50:125-136.
25. Wang S, Skorczewski J, Feng X, Mei L, Murphy-Ullrich JE: Glucose up-regulates throm-bospondin 1 gene transcription and transforming growth factor-ß activity through antagonism of CGMP-dependent protein ki-nase repression via upstream stimulatory factor 2. J Biol Chem 2004; 279: 34311-34322.
26. Skowasch D, Jabs A, Andrie R, Dinkelbach S, Luderitz B, Bauriedel G: Presence of bone-marrow-and neural-crest-derived cells in intimal hyperplasia at the time of clinical in-stent restenosis. Cardiovasc Res 2003; 60: 684-691.
27. Owens GK: Regulation of differentiation of vascular smooth muscle cells. Physiol Rev 1995; 75:487-517.
28. Glukhova MA, Frid MG, Shekhonin BV, Vasilevskaya TD, Grunwald J, Saginati M, Koteliansky VE: Expression of extra domain a fibronectin sequence in vascular smooth muscle cells is phenotype dependent. J Cell Biol 1989; 109: 357-366.
29. Lincoln TM, Dey NB, Boerth NJ, Cornwell TL, Soff GA: Nitric oxide-cyclic GMP pathway regulates vascular smooth muscle cell phenotypic modulation: implications in vascular diseases. Acta Physiol Scand 1998; 164: 507-515.
30. Anderson PG, Boerth NJ, Liu M, McNamara DB, Cornwell TL, Lincoln TM: Cyclic GMP-dependent protein kinase expression in coronary arterial smooth muscle in response to balloon catheter injury. Arterioscler Thromb Vasc Biol 2000; 20:2192-2197.
31. Emura M OA, Horino M, Arndt W, Kamino K, Hirohashi S: Development of myofibro-blasts from human bone marrow mesenchy-mal stem cells cocultured with human colon carcinoma cells and TGF ß 1. In Vitro Cell Dev Biol Anim 2000; 36: 77-80.
32. Murphy-Ullrich JE, Schultz-Cherry S, Hook M: Transforming growth factor-ß complexes with thrombospondin. Mol Biol Cell 1992; 3:181-188.
33. Annis DS, Murphy-Ullrich JE, Mosher DF: Function-blocking antithrombospondin-1 monoclonal antibodies. J Thromb Haemost 2006; 4: 459-468.
34. Schultz-Cherry S, Murphy-Ullrich JE: Thrombospondin causes activation of latent transforming growth factor-ß secreted by endothelial cells by a novel mechanism. J Cell Biol 1993; 122:923-932.
35. Xing D, Feng W, Miller AP, Weathington NM, Chen YF, Novak L, Blalock JE, Oparil S: Estrogen modulates TNF-α-induced inflammatory responses in rat aortic smooth muscle cells through estrogen receptor-beta activation. Am J Physiol Heart Circ Physiol 2007; 292:H2607-H2612.
36. Dey NB, Boerth NJ, Murphy-Ullrich JE, Chang PL, Prince CW, Lincoln TM: Cyclic GMP-dependent protein kinase inhibits os-teopontin and thrombospondin production in rat aortic smooth muscle cells. Circ Res 1998; 82: 139-146.
37. Misra P, Reddy PC, Shukla D, Caldito GC, Yerra L, Aw TY: In-stent stenosis: potential role of increased oxidative stress and gluta-thione-linked detoxification mechanisms. Angiology 2008; 59: 469-474.
38. Lincoln TM, Dey N, Sellak H: Invited review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression. J Appl Physiol 2001; 91: 1421-1430.
39. Bobik A: Transforming growth factor-ß and vascular disorders. Arterioscler Thromb Vasc Biol 2006; 26:1712-1720.
40. Grainger DJ: Transforming growth factor ß and atherosclerosis: so far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol 2004; 24: 399-404.
41. Owens GK, Geisterfer AA, Yang YW, Ko-moriya A: Transforming growth factor-ß-induced growth inhibition and cellular hypertrophy in cultured vascular smooth muscle cells. J Cell Biol 1988; 107: 771-780.
42. Majesky MW, Lindner V, Twardzik DR Schwartz SM, Reidy MA: Production of transforming growth factor ß 1 during repair of arterial injury. J Clin Invest 1991; 88: 904-910.
43. Nikol S, Isner JM, Pickering JG, Kearney M, Leclerc G, Weir L: Expression of transforming growth factor-ß 1 is increased in human vascular restenosis lesions. J Clin Invest 1992; 90: 1582-1592.
44. Rasmussen LM, Wolf YG, Ruoslahti E: Vascular smooth muscle cells from injured rat aortas display elevated matrix production associated with transforming growth factor-ß activity. Am J Pathol 1995; 147: 1041-1048.
45. Ward MR, Agrotis A, Kanellakis P, Hall J, Jennings G, Bobik A: Tranilast prevents activation of transforming growth factor-beta system, leukocyte accumulation, and neo-intimal growth in porcine coronary arteries after stenting. Arterioscler Thromb Vasc Biol 2002; 22:940-948.
46. Wolf YG, Rasmussen LM, Ruoslahti E: Antibodies against transforming growth factor-ß 1 suppress intimal hyperplasia in a rat model. J Clin Invest 1994; 93:1172-1178.
47. Smith JD, Bryant SR, Couper LL, Vary CP, Gotwals PJ, Koteliansky VE, Lindner V: Soluble transforming growth factor-ß type II receptor inhibits negative remodeling, fibro-blast transdifferentiation, and intimal lesion formation but not endothelial growth. Circ Res 1999; 84: 1212-1222.
48. Joner M, Farb A, Cheng Q, Finn AV, Acam-pado E, Burke AP, Skorija K, Creighton W, Kolodgie FD, Gold HK, Virmani R: Piogli-tazone inhibits in-stent restenosis in atherosclerotic rabbits by targeting transforming growth factor-ß and MCP-1. Arterioscler Thromb Vasc Biol 2007; 27: 182-189.
49. Majack RA, Goodman LV, Dixit VM: Cell surface thrombospondin is functionally essential for vascular smooth muscle cell proliferation. J Cell Biol 1988; 106: 415-422.
50. Yabkowitz R, Mansfield PJ, Ryan US, Su-chard SJ: Thrombospondin mediates migration and potentiates platelet-derived growth factor-dependent migration of calf pulmonary artery smooth muscle cells. J Cell Physiol 1993; 157: 24-32.
51. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, Bouck NP: A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 1990; 87:6624-6628.
52. Majack RA, Cook SC, Bornstein P: Platelet-derived growth factor and heparin-like gly-cosaminoglycans regulate thrombospondin synthesis and deposition in the matrix by smooth muscle cells. J Cell Biol 1985; 101: 1059-1070.
53. Zohlnhofer D, Klein CA, Richter T, Brandl R, Murr A, Nuhrenberg T, Schomig A, Baeuerle PA, Neumann FJ: Gene expression profiling of human stent-induced neointima by cDNA array analysis of microscopic specimens retrieved by helix cutter atherectomy: Detection of fk506-binding protein 12 upregula-tion. Circulation 2001; 103:1396-1402.
54. Zhang QJ, Goddard M, Shanahan C, Shapiro L, Bennett M: Differential gene expression in vascular smooth muscle cells in primary atherosclerosis and in stent stenosis in humans. Arterioscler Thromb Vasc Biol 2002; 22: 2030-2036.
55. Riessen R, Kearney M, Lawler J, Isner JM: Immunolocalization of thrombospondin-1 in human atherosclerotic and restenotic arteries. Am Heart J 1998; 135: 357-364.
56. Chen D, Asahara T, Krasinski K, Witzen-bichler B, Yang J, Magner M, Kearney M, Frazier WA, Isner JM, Andres V: Antibody blockade of thrombospondin accelerates re-endothelialization and reduces neointima formation in balloon-injured rat carotid artery. Circulation 1999; 100:849-854.
57. Moura R, Tjwa M, Vandervoort P, Cludts K, Hoylaerts MF: Thrombospondin-1 activates medial smooth muscle cells and triggers neointima formation upon mouse carotid artery ligation. Arterioscler Thromb Vasc Biol 2007; 27: 2163-2169.
58. Budhani F, Leonard KA, Bergdahl A, Gao J, Lawler J, Davis EC: Vascular response to in-tra-arterial injury in the thrombospondin-1 null mouse. J Mol Cell Cardiol 2007; 43:210-214.
59. Anderson PG, Boerth NJ, Liu M, McNamara DB, Cornwell TL, Lincoln TM: Cyclic GMP-dependent protein kinase expression in coronary arterial smooth muscle in response to balloon catheter injury. Arterioscler Thromb Vasc Biol 2000; 20:2192-2197.
60. Sinnaeve P, Chiche JD, Gillijns H, Van Pelt N, Wirthlin D, Van De Werf F, Collen D, Bloch KD, Janssens S: Overexpression of a constitutively active protein kinase G mutant reduces neointima formation and in-stent restenosis. Circulation 2002; 105: 2911-2916.
61. Wang S, Shiva S, Poczatek MH, Darley-Us-mar V Murphy-Ullrich JE: Nitric oxide and cGMP-dependent protein kinase regulation of glucose-mediated thrombospondin 1-de-pendent transforming growth factor-ß activation in mesangial cells. J Biol Chem 2002; 277:9880-9888.
62. Saura M, Zaragoza C, Herranz B, Griera M, Diez-Marques L, Rodriguez-Puyol D, Rodriguez-Puyol M: Nitric oxide regulates transforming growth factor-ß signaling in endothelial cells. Circ Res 2005; 97:1115-1123.
63. Li P, Oparil S, Novak L, Cao X, Shi W, Lucas J, Chen YF: ANP signaling inhibits TGF-ß-induced Smad2 and Smad3 nuclear translo-cation and extracellular matrix expression in rat pulmonary arterial smooth muscle cells. J Appl Physiol 2007; 102:390-398.
64. Ozmen I, Naziroglu M, Okutan R: Comparative study of antioxidant enzymes in tissues surrounding implant in rabbits. Cell Bio-chem Funct 2006; 24:275-281.
65. Ball M, O'Brien A, Dolan F, Abbas G, McLaughlin JA: Macrophage esponses to vascular stent coatings. J Biomed Mater Res A 2004; 70: 380-390.
66. Do YS, Kao EY, Ganaha F, Minamiguchi H, Sugimoto K, Lee J, Elkins CJ, Amabile PG, Kuo MD, Wang DS, Waugh JM, Dake MD: In-stent restenosis limitation with stent-based controlled-release nitric oxide: Initial results in rabbits. Radiology 2004; 230:377-382.
67. Barcellos-Hoff MH, Dix TA: Redox-mediat-ed activation of latent transforming growth factor-ß 1. Mol Endocrinol 1996; 10:1077-1083.
68. Cucoranu I, Clempus R, Dikalova A, Phelan PJ, Ariyan S, Dikalov S, Sorescu D: NAD(P)H oxidase 4 mediates transforming growth factor-ß1- induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res 2005; 97: 900-907.
69. Isenberg JS, Wink DA, Roberts DD: Throm-bospondin-1 antagonizes nitric oxide-stimulated vascular smooth muscle cell responses. Cardiovasc Res 2006; 71: 785-793.
70. Craven PA, Studer RK, Felder J, Phillips S, DeRubertis FR: Nitric oxide inhibition of transforming growth factor-ß and collagen synthesis in mesangial cells. Diabetes 1997; 46: 671-681.
71. Wang S, Shiva S, Poczatek MH, Darley-Us-mar V, Murphy-Ullrich JE: Nitric oxide and cGMP-dependent protein kinase regulation of glucose-mediated thrombospondin 1-de-pendent transforming growth factor-ß activation in mesangial cells. J Biol Chem 2002; 277:9880-9888.
72. Sheriff TS, Cope S, Ekwegh M: Calmagite dye oxidation using in situ generated hydrogen peroxide catalysed by manganese(II) ions. Dalton Trans 2007: 5119-5122.